two
antimicrobi
peptid
four
synthet
analog
compar
vitro
vivo
antimicrobi
efficaci
peptid
prove
activ
vitro
micromolar
concentr
rang
clinic
isol
includ
antibioticresist
strain
two
analog
effect
toward
gramneg
toward
gramposit
organ
addit
provid
protect
vitro
human
herp
simplex
viru
type
parent
peptid
analog
protect
mice
lethal
ip
infect
acut
periton
model
peptid
dose
significantli
lower
toxic
anim
suggest
satisfactori
therapeut
index
emerg
clinic
bacteri
strain
exhibit
resist
convent
antibiot
urg
search
novel
antiinfect
agent
among
compound
current
investig
therapeut
potenti
number
cation
antimicrobi
peptid
innat
immun
system
synthet
deriv
cation
antimicrobi
peptid
present
live
organ
firstlin
hostdefens
mechan
invad
microb
peptid
rapidli
inactiv
bacteri
fungal
viral
pathogen
mechan
case
mediat
disrupt
integr
microbi
membran
rel
nonspecif
mechan
difficult
evad
suscept
bacteria
indic
rel
rare
select
bacteri
strain
resist
cation
peptid
consid
interest
featur
peptid
view
develop
antiinfect
drug
studi
investig
therapeut
potenti
two
natur
peptid
belong
mammalian
cathelicidin
peptid
famili
molecul
denot
bmap
acronym
bovin
myeloid
antimicrobi
peptid
indic
antimicrobi
compon
bovin
neutrophil
two
peptid
amino
acid
residu
long
respect
ctermin
amid
share
sequenc
ident
addit
similar
prior
structur
studi
suggest
molecul
includ
ntermin
region
undergo
conform
membran
mimick
environ
nonhel
hydrophob
ctermin
region
bmap
kill
gramneg
posit
bacteria
fungal
speci
micromolar
concentr
retain
strong
broad
spectrum
antimicrobi
activ
presenc
physiolog
salt
concentr
addit
vitro
antibacteri
antiparasit
efficaci
leptospira
interrogan
serovar
cryptosporidium
parvum
recent
report
mechan
action
peptid
base
abil
rapidli
bind
permeabil
membran
target
microorgan
howev
prove
toxic
mammalian
cell
concentr
rang
suggest
poor
discrimin
prokaryot
eukaryot
cell
membran
structureact
relationship
sar
studi
aim
increas
select
toward
microbi
organ
led
design
truncat
bmap
deriv
compris
ntermin
sequenc
lack
hydrophob
ctermin
region
compound
denot
virtual
devoid
cytotox
haemolyt
activ
display
antimicrobi
potenc
compar
slightli
lower
parent
bmap
peptid
similar
properti
also
share
analog
modifi
ctermin
region
name
collect
sar
studi
suggest
hydrophob
ctermin
tail
major
determin
toxic
bmap
molecul
mammalian
cell
import
step
investig
therapeut
potenti
extend
function
analysi
bmap
determin
vitro
vivo
efficaci
specif
analys
vitro
activ
analog
wide
panel
gramneg
posit
clinic
isol
also
includ
mani
antibioticresist
strain
human
herp
simplex
viru
type
addit
peptid
compris
ctermin
region
lack
ntermin
residu
also
test
potenti
protect
vivo
infect
gramneg
posit
organ
assess
use
mous
acut
periton
model
fmocpalpegp
resin
coupl
reagent
peptid
synthesi
fmocamino
acid
purchas
appli
biosystem
foster
citi
usa
novabiochem
laufelfingel
switzerland
chemimpex
wood
dale
il
usa
peptid
synthesisgrad
n
ndimethylformamid
dichloromethan
dimethylsulfoxid
piperidin
hplcgrade
acetonitril
biosolv
valkenswaard
netherland
trifluoroacet
acid
nmethylmorpholin
trifluoroethanol
tfe
obtain
acro
chimica
beers
belgium
bicyclo
dbu
nacetylimidazol
sigmaaldrich
st
loui
mo
usa
peptid
analog
synthes
previous
describ
milligen
autom
synthes
appli
biosystem
foster
citi
usa
use
fmoc
chemistri
side
chain
protect
group
follow
trityl
trt
tbutyl
tbu
tyr
ser
tbutyloxycarbonyl
boc
ly
trp
pbf
arg
obtain
ctermin
amid
peptid
fmocpalpegp
resin
meqg
use
synthesi
carri
c
n
ndimethylformamid
dmf
sixfold
excess
fmocamino
acid
activ
situ
equival
amount
tetrafluorobor
tbtu
presenc
n
nmethylmorpholin
improv
yield
difficult
coupl
perform
eightfold
amino
acid
excess
use
equimolar
amount
hexafluorophosph
hatu
coupl
agent
cleavag
deprotect
mixtur
trifluoroacet
acidwaterthioanisolephenolethandithioltriisopropylsilan
vv
h
room
temperatur
crude
peptid
repeatedli
extract
methyl
butyl
ether
purifi
revers
phase
high
perform
liquid
chromatographi
rphplc
prepar
mm
deltapak
column
water
bedford
usa
use
appropri
wateracetonitril
gradient
presenc
trifluoroacet
acid
molecular
mass
determin
electrospray
mass
spectrometri
esm
use
api
instrument
pe
sciex
toronto
canada
purifi
peptid
dissolv
tfa
approxim
mm
concentr
divid
small
aliquot
kept
frozen
c
use
concentr
determin
nm
consid
molar
extinct
coeffici
phe
residu
peptid
measur
nm
use
molar
extinct
coeffici
trp
tyr
total
gramposit
staphylococcu
aureu
enterococcu
faecali
enterococcu
faecium
streptococcu
agalactia
gramneg
acinetobact
baumanni
pseudomona
aeruginosa
serratia
marcescen
bacteri
strain
test
studi
clinic
isol
routin
character
antibioticresist
kindli
provid
prof
e
tonin
depart
biomed
scienc
univers
triest
escherichia
coli
bort
use
acut
periton
anim
model
gener
gift
prof
p
abraham
academ
medic
center
univers
amsterdam
strain
store
c
subcultur
luriabertani
lb
broth
prior
use
vitro
antibacteri
activ
purifi
bmap
peptid
analog
determin
minimum
inhibitori
concentr
mic
microdilut
suscept
test
microtit
plate
accord
guidelin
nation
committe
clinic
laboratori
standard
nccl
activ
measur
muellerhinton
broth
difco
logarithmicphas
microorgan
previous
report
porcin
respiratori
corona
viru
prcv
kindli
provid
dr
wunderli
institut
medic
virolog
dr
engel
institut
virolog
faculti
veterinari
medicin
univers
titrat
inocul
cell
swine
testicular
cell
prcv
cell
kindli
provid
dr
engel
dilut
use
endpoint
dilut
method
reed
muench
cell
grown
minim
essenti
medium
mem
earl
salt
lglutamin
gibco
brl
supplement
foetal
calf
serum
fc
gibco
brl
uml
penicillin
gml
streptomycin
gibco
brl
swine
testicular
cell
cultur
iscov
modifi
dulbecco
medium
without
lglutamin
contain
mm
hepe
nonessenti
amino
acid
mm
napyruv
neutral
red
uptak
assay
perform
follow
procedur
base
borenfreund
puerner
briefli
h
infect
mainten
medium
remov
cell
incub
h
mem
contain
gml
neutral
red
fluka
l
per
well
cell
wash
fix
l
formaldehyd
cacl
dye
taken
cell
extract
use
l
acet
acid
ethanol
absorb
measur
nm
dynatech
micropl
reader
dynatech
laboratori
inc
chantilli
va
usa
sampl
test
triplic
percent
protect
achiev
compound
infect
cell
calcul
describ
pauwel
et
al
increas
concentr
peptid
dissolv
mem
incub
confluent
cell
monolay
infect
tcdi
tissu
cultur
plate
min
c
co
remov
medium
cell
monolay
wash
phosphatebuff
salin
pb
incub
mem
h
inhibit
cytopath
effect
assess
light
microscopi
measur
neutral
red
uptak
assay
use
infect
vero
cell
control
peptid
cytotox
evalu
use
assay
incub
uninfect
cell
serial
dilut
peptid
min
c
co
confluent
cell
monolay
infect
treat
peptid
describ
previou
paragraph
h
incub
c
co
plate
frozen
thaw
three
time
tenfold
dilut
supernat
use
infect
confluent
cell
monolay
grown
plate
quantifi
inhibit
h
c
co
inoculum
remov
cell
monolay
wash
pb
overlaid
mem
supplement
carboxymethyl
cellulos
fc
uml
penicillin
gml
streptomycin
incub
c
co
day
remov
medium
fixat
methanol
monolay
stain
crystal
violet
plaqu
number
count
result
repeat
experi
perform
triplic
express
percentag
plaqu
inhibit
comparison
untreat
control
cell
monolay
vivo
experi
male
balbc
mice
approxim
g
week
age
obtain
harlan
nossan
harlan
nossan
srl
correzzana
milan
itali
vivo
toxic
peptid
investig
inject
mice
increas
amount
bmap
peptid
dissolv
steril
pb
via
ip
ml
per
mous
iv
ml
per
mous
control
receiv
vehicl
alon
anim
behaviour
surviv
monitor
period
ld
calcul
accord
litchfield
wilcoxon
experi
encapsul
strain
e
coli
bort
methicillinresist
aureu
mrsa
refer
strain
p
aeruginosa
atcc
grown
muellerhinton
broth
inocula
contain
amount
bacteria
expect
result
mortal
prepar
dilut
logphas
cultur
pb
depend
test
organ
inocula
rang
cfu
e
coli
bort
cfu
p
aeruginosa
atcc
cfu
per
mous
mrsa
least
mice
per
dose
level
infect
monitor
surviv
period
infect
mic
valu
present
mean
least
four
independ
experi
statist
signific
differ
mortal
vivo
experi
determin
fisher
exact
test
p
valu
accept
indic
signific
sequenc
bmap
peptid
use
shown
tabl
antibacteri
activ
peptid
test
microdilut
suscept
assay
toward
bacteri
isol
includ
varieti
clinic
relev
antibioticresist
speci
mrsa
vancomycinresist
e
faecali
vref
fig
multiresist
strain
p
aeruginosa
baumannii
fig
display
broadspectrum
activ
mic
valu
rang
case
valu
confirm
extend
previous
obtain
limit
panel
atcc
strain
despit
structur
similar
two
peptid
reveal
differ
somewhat
complementari
spectra
activ
ie
effect
gramneg
speci
mic
valu
fig
tabl
wherea
show
better
activ
gramposit
strain
mic
valu
fig
tabl
importantli
similar
even
lower
mic
valu
observ
activ
toward
antibioticsuscept
versu
antibioticresist
strain
eg
mssa
versu
mrsa
strain
vsef
versu
vref
strain
compar
fig
tabl
convers
slightli
less
effect
gramposit
strain
show
significantli
improv
activ
gramneg
strain
thu
base
vitro
data
remov
ctermin
hydrophob
sequenc
result
improv
select
toward
bacteri
versu
mammalian
cell
alreadi
report
also
toward
gramneg
versu
gramposit
microorgan
fragment
lack
part
ntermin
maintain
ctermin
hydrophob
region
show
compar
activ
gramposit
neg
microorgan
slightli
less
potent
p
aeruginosa
mic
valu
increas
fig
modifi
analog
character
hydrophil
ctermin
region
highli
potent
gramneg
strain
mic
valu
significantli
lower
mic
toward
baumannii
p
aeruginosa
fig
contrast
analog
show
mark
decreas
activ
gramposit
strain
mic
remark
except
three
highli
suscept
agalactia
strain
abil
synthet
fragment
inhibit
cytopath
effect
determin
neutral
red
uptak
assay
use
broad
rang
peptid
concentr
cell
monolay
incub
tcdi
particl
peptid
min
wash
incub
absenc
peptid
h
observ
cell
growth
poorli
cytotox
cell
take
neutral
red
dye
concentr
peptid
provid
protect
inhibit
viral
replic
extent
assess
viru
yield
inhibit
assay
tabl
also
toxic
vero
cell
unlik
peptid
exert
protect
viral
infect
concentr
test
shown
despit
structur
resembl
cytotox
even
lowest
peptid
concentr
test
shown
therebi
preclud
evalu
antivir
activ
peptid
also
test
porcin
respiratori
corona
viru
use
swine
testicular
st
cell
howev
none
peptid
prove
activ
viru
shown
support
poor
antivir
activ
peptid
test
confluent
cell
incub
min
c
wash
resuspend
growth
medium
cell
surviv
determin
measur
uptak
neutral
red
incub
h
c
b
cell
incub
peptid
viral
particl
tcdi
min
c
wash
resuspend
growth
medium
cell
protect
determin
measur
uptak
neutral
red
h
incub
c
c
quantif
inhibit
perform
viru
yield
inhibit
assay
describ
section
result
mean
two
independ
experi
perform
triplic
first
step
evalu
therapeut
potenti
bmap
peptid
vivo
toxic
parent
peptid
fragment
determin
mice
inject
intraperiton
andor
intraven
increas
singl
peptid
dose
toxic
observ
peptid
administ
ip
mgkg
wherea
dose
mgkg
result
mortal
within
day
inject
ld
valu
determin
rang
mgkg
toxic
intraven
administr
prove
much
higher
ld
valu
mgkg
respect
result
indic
compound
safe
via
iv
therefor
therapeut
potenti
restrict
topic
applic
potenti
bmap
protect
mice
bacteri
challeng
test
model
acut
periton
induc
ip
inject
lethal
dose
p
aeruginosa
atcc
cfuml
e
coli
bort
cfuml
encapsul
strain
isol
neonat
mening
patient
mrsa
cfuml
strain
suscept
bmap
vitro
micromolar
concentr
rang
shown
tabl
adult
male
balbc
mice
infect
ip
lethal
dose
test
microorgan
immedi
follow
singl
dose
peptid
number
survivor
monitor
week
compar
control
mice
receiv
lethal
bacteri
challeng
vehicl
result
experi
summar
tabl
littl
mgkg
result
full
protect
e
coliinfect
mice
higher
dose
mgkg
peptid
requir
obtain
protect
p
aeruginosa
convers
poorli
effect
aureu
even
mgkg
peptid
concentr
provid
protect
aureu
e
coliinfect
mice
respect
mgkg
compound
somewhat
less
effect
p
aeruginosa
protect
dose
mgkg
vivo
result
thu
reflect
vitro
behaviour
two
peptid
effect
gramneg
gramposit
bacteri
strain
effect
fragment
test
mice
ip
infect
p
aeruginosa
mrsa
compound
administ
ip
mgkg
immedi
bacteri
challeng
show
protect
p
aeruginosainfect
mice
mgkg
neither
peptid
effect
aureu
challeng
data
shown
final
protect
effect
lethal
dose
ip
inject
p
aeruginosa
test
mgkg
former
dose
ineffect
latter
two
dose
protect
infect
mice
respect
data
shown
analog
test
mrsainduc
periton
model
sinc
prove
inact
vitro
gramposit
microorgan
studi
investig
vitro
vivo
activ
two
cathelicidin
peptid
fragment
analog
deriv
vitro
activ
test
wide
panel
clinic
isol
includ
mrsa
vref
strain
well
baumannii
p
aeruginosa
multiresist
strain
result
indic
broad
spectrum
activ
parent
compar
effect
antibioticresist
antibioticsuscept
isol
confirm
mechan
action
peptid
base
abil
permeabil
bacteri
membran
differ
antibiot
strain
test
resist
truncat
substitut
analog
design
probe
import
hydrophob
ctermin
region
show
signific
differ
activ
compar
parent
bmap
lack
ctermin
region
replac
hydrophob
residu
region
hydrophil
one
effect
toward
gramneg
microorgan
case
led
improv
activ
special
observ
convers
modif
result
decreas
activ
gramposit
strain
notabl
except
agalactia
remain
highli
suscept
interest
note
decreas
activ
gramposit
bacteria
parallel
decreas
cytotox
toward
mammalian
cell
observ
upon
remov
modif
ctermin
tail
understand
differ
activ
requir
deeper
investig
bacteri
surfac
compon
interact
peptid
indic
potent
wide
spectrum
vitro
antibacteri
activ
result
studi
support
antivir
efficaci
bmap
peptid
fact
provid
protect
vitro
wherea
peptid
ineffect
noncytotox
concentr
result
obtain
vitro
assay
prompt
us
exploit
vivo
potenti
peptid
lethal
bacteri
challeng
anim
use
acut
periton
model
mice
suggest
result
vivo
toxic
test
indic
much
better
ld
ip
rather
iv
administr
peptid
vivo
result
use
parent
bmap
encourag
parallel
obtain
vitro
highli
protect
e
coli
p
aeruginosa
protect
respect
mgkg
consider
less
effect
ip
challeng
aureu
tabl
convers
administr
mgkg
result
protect
ip
inject
mrsa
strain
less
effect
e
coli
p
aeruginosa
importantli
protect
achiev
peptid
dose
significantli
lower
toxic
anim
ie
ip
toxic
mgkg
suggest
satisfactori
therapeut
index
compound
keep
vitro
result
also
protect
mice
lethal
ip
dose
p
aeruginosa
wherea
fragment
effect
vitro
vivo
peptid
poorli
protect
mous
model
use
suggest
hydrophob
ctermin
region
import
vivo
activ
despit
wealth
publish
vitro
activ
studi
antimicrobi
peptid
antibioticresist
clinic
isol
publish
report
vivo
activ
cathelicidin
peptid
structur
test
mous
model
acut
periton
induc
aureu
p
aeruginosa
effect
dose
compar
well
highli
potent
analog
prove
effect
reduc
oral
microflora
human
suggest
antimicrobi
peptid
may
use
treatment
oral
infect
vivo
studi
examin
effect
exert
sheep
cathelicidin
peptid
ovin
model
acut
pulmonari
infect
peptid
highli
similar
ident
prove
effect
pulmonari
deposit
lamb
pneumonia
model
induc
mannheimia
haemolytica
reduc
bacteri
concentr
bronchoalveolar
fluid
consolid
pulmonari
tissu
well
sever
lesion
lung
suggest
may
find
applic
treatment
respiratori
tract
infect
vivo
studi
perform
indolicidin
bovin
cathelicidin
peptid
use
anim
model
system
fungal
infect
caus
intraven
inject
aspergillu
fumigatu
spore
free
indolicidin
highli
toxic
mice
inject
iv
treat
anim
die
mgkg
peptid
wherea
administr
peptid
encapsul
liposom
significantli
reduc
toxic
liposom
entrap
indolicidin
mgkg
consider
increas
anim
surviv
suggest
liposom
carrier
may
improv
therapeut
index
toxic
peptid
final
indolicidin
antimicrobi
peptid
investig
three
rat
model
septic
shock
treatment
peptid
use
studi
result
signific
reduct
plasma
endotoxin
concentr
reduc
rate
anim
death
compar
control
addit
report
vivo
studi
sever
clinic
trial
perform
current
underway
analog
deriv
natur
antimicrobi
peptid
result
far
obtain
indic
despit
failur
case
peptid
still
therapeut
potenti
particularli
topic
applic
